Treatment of Superficial Femoral Artery Restenosis

Miller, A.; Takahashi, Edwin A.; Harmsen, William S.; Mara, Kristin C.; Misra, Sanjay

doi:10.1016/j.jvir.2017.07.032

Cited by 13 publications

(7 citation statements)

References 31 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been presented by other researchers with restenosis frequencies of 19-37% [13][14][15]. Some studies suggest that the use of BMS has similar outcomes to using balloon angioplasty (PTA) alone [16].…”

Section: Discussionsupporting

confidence: 87%

Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD

Falkowski

Bogacki

Szemitko

2020

JCM

View full text Add to dashboard Cite

The use of drug-coated devices in intravascular therapy is aimed at preventing neointimal hyperplasia caused by excessive proliferation of vascular smooth muscle and thereby restenosis. Although its use seemed initially promising, a recent publication has shown an increased risk of mortality with paclitaxel-coated devices, and there is an urgent need to reaffirm assessments of drug-eluting stents (DES). Objective: The aim of the study was to compare mortality and effectiveness of paclitaxel-coated stents and bare-metal stents (BMS) in the treatment of peripheral arterial disease (PAD) with long-term follow-up. Materials and methods: In a single center randomized study, 256 patients with PAD were treated intravascularly with stent implantation. Patients were randomized into two groups: the first (n = 126) were treated with DES, and the second (n = 130) were treated with BMS. The study included evaluation after the procedure, after about 6 months and 36 months. Co-morbidities, with risks for atherosclerosis, were analyzed in all patients. Patients were evaluated for clinical outcome, restenosis frequency, and safety (complications and total mortality). Results: Clinical benefit at the end of the investigation was statistically significantly better in the DES group compared with the BMS group: 85.7% versus 66.2% (p = 0.0003), respectively. Restenosis occurred significantly less frequently in patients with DES: 16.0% versus BMS: 35.0%, p = 0.012. There was no significant effect of comorbidities on the frequency of restenoses. There were no differences in all-cause mortality over the three years with paclitaxel and no-paclitaxel stents cohorts (8.7% versus 7.1%; long-rank p = 0.575). No association was found with mortality and treatment with DES or BMS. Conclusions: The use of paclitaxel-coated stents gave good clinical benefit and caused a significantly lower frequency of restenosis compared to bare-metal stents. The use of paclitaxel-coated stents did not increase mortality.

show abstract

Section: Discussionsupporting

confidence: 87%

Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD

Falkowski

Bogacki

Szemitko

2020

JCM

View full text Add to dashboard Cite

show abstract

“…Smoking, diabetes mellitus, and hyperlipidemia are demonstrated predictors for PAD and in-stent re-stenosis [15]. Although taking precautions against these factors may decrease in-stent re-stenosis in the short term, stent obstructions cannot be prevented in the long term [16]. Therefore, all precautions should be taken to provide stent patency.…”

Section: Discussionmentioning

confidence: 99%

Effects of mean platelet volume and platelet counts on peripheral biodegradable stent restenosis

Akgül¹,

Engin²,

Özyazicioğlu³

2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: Thrombocytes play a key role in atherosclerosis and acute vascular events. The purpose of this study is to investigate the association between mean platelet volume (MPV), platelet counts as well as other hematological parameters and biodegradable stent restenosis. Methods: 53 patients who underwent percutaneous biodegradable peripheral stent placement procedure were included in this retrospective cohort study. Blood samples were collected a day before the operation. Patients were followed for a mean of 6 months and Doppler ultrasonography (DUSG) was performed for control examination. According to the DUSG results, patients were divided into two groups: Group 1 included patients with ≥50% in-stent re-stenosis and Group 2, with <50% in-stent re-stenosis. Results: The mean age of the patients was 58.1 (6.7) years. 6 (11.3%) patients were female and 47 (88.7%) patients were male. Eight (15%) had iliac artery and 45 (84.9%) had superficial femoral artery stenosis. Doppler US reports showed that 11 (20.8%) patients had ≥50% in-stent re-stenosis (Group 1). Re-stenosis rates were higher at younger ages (P=0.020). There was no statistically difference between the groups in terms of gender (P=0.636), MPV (P=0.210), PLT counts (P=0.129) or any other hematologic parameters. Conclusion: Several studies have shown that some blood parameters, especially MPV, are effective on coronary and peripheral stent stenosis. In our study, we found that none of the hematologic or common blood parameters can predict biodegradable stents re-stenosis.

show abstract

“…The rates of in-stent restenosis can be decreased by taking several precautions to these clinical features. Although these precautions are taken, in-stent restenosis of the SFA is observed to have high rates especially in mid- and long-term follow-up [ 18 – 20 ]. Therefore, knowing the additional predictors of the in-stent restenosis of the SFA which can be used easily and cost-effectively in daily practice may improve the clinical outcomes such as stent patency.…”

Section: Discussionmentioning

confidence: 99%

Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent Restenosis of the Superficial Femoral Artery Stents in Follow-Up

Karaüzüm

Bildirici

Derviş

et al. 2018

Cardiology Research and Practice

View full text Add to dashboard Cite

Background The mean platelet volume (MPV), the most commonly used measure of the platelet size, is a cheap and easy-to-use marker of the platelet activation. We aimed to evaluate the relationship between preprocedural MPV and other hematologic blood count parameters and in-stent restenosis in patients with superficial femoral artery (SFA) stenting. Methods and Results The consecutive 118 patients who successfully underwent endovascular stenting of the SFA were enrolled retrospectively in the study. The mean follow-up was 23 ± 12 months. The in-stent restenosis was observed in 42 patients (35.6%). There were no statistically significant differences between the restenosis group and no-restenosis group in terms of age, gender, and smoking (p=0.116, p=0.924, and p=0.428, resp.). In the restenosis group, the MPV level was markedly higher than that in the no-restenosis group, and it was statistically significant (p < 0.001). According to the ROC curve analysis, the optimal cutoff value of the MPV to determine the restenosis was >8.7 fL, and the level of the MPV >8.7 fL was a strong predictor of the restenosis (p < 0.001) in logistic regression analysis. Conclusions The measurement of the preprocedural MPV levels may help to identify high-risk patients for development of the in-stent restenosis. These patients may benefit from an aggresive antiplatelet therapy and close follow-up.

show abstract

Treatment of Superficial Femoral Artery Restenosis

Cited by 13 publications

References 31 publications

Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD

Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD

Effects of mean platelet volume and platelet counts on peripheral biodegradable stent restenosis

Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent Restenosis of the Superficial Femoral Artery Stents in Follow-Up

Contact Info

Product

Resources

About